



Praxis Precision Medicines to Participate in Upcoming Investor Conferences

September 5, 2024 at 8:00 AM EDT

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be attending and presenting at two upcoming conferences:

H.C. Wainwright 26th Annual Global Investment Conference

Format: Fireside Chat

Presentation date and time: September 9, 2024 at 12:00pm EDT

Location: Lotte New York Palace Hotel, New York, NY

Webcast: [here](#)

Baird Global Healthcare Conference

Format: Fireside Chat

Presentation date and time: September 11, 2024 at 2:35pm EDT

Location: InterContinental Barclay Hotel, New York, NY

The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective H.C. Wainwright and/or Baird representatives to request meetings. A replay of the presentation will be posted, when available, to Praxis' website on the "[Events and Presentations](#)" page under the investor section of the [website](#) for 90 days.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on [Facebook](#), [LinkedIn](#) and [Twitter/X](#).

Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576